PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Prothena Achieves Orphan Drug Status in EU for Lead Program NEOD001
Potential Treatment for Systemic Amyloidoses Also Has US Designation
View HTML
Toggle Summary Prothena to Ring NASDAQ Stock Market Opening Bell
DUBLIN, Ireland, Feb. 13, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced that its President and Chief Executive Officer,
View HTML
Toggle Summary Prothena Announces Addition of Industry Veterans to Board of Directors
Richard T. Collier and Shane Cooke Join Board of Directors
View HTML
Toggle Summary Prothena Begins Trading on NASDAQ Global Market Under Symbol "PRTA"
Company Completes Successful Separation and Share Distribution From Elan
View HTML
Toggle Summary Prothena to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
Prothena to Present at the Lazard Capital Markets 9th Annual Healthcare Conference South San Francisco, CA, November 13, 2012 – Prothena Corporation, a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today
View HTML
Toggle Summary Elan Announces Plan to Spin-Off Discovery Science And Neotope Biosciences to Shareholders
Elan Announces Plan to Spin-Off Discovery Science And Neotope Biosciences to Shareholders Creates two independent, unique companies Transaction aligns assets, timelines, and risk/reward Elan to become immediately profitable and a high growth company Targeting $1.00 earnings per share by 2015 with
View HTML